All In Biotech

Drug Trial Radar · NCT01704716

High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,569

Actual

Start

Feb 1, 2002

Primary completion

Jan 30, 2025

Study completion Jan 30, 2025

Sponsor

Lead sponsor
St. Anna KinderkrebsforschungAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 month, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis).The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunotherapy (isotretinoin and ch14.18/CHO (Dinutuximab beta, Qarziba ® without s.c. aldesleukin (IL-2)). Last randomisation question (R4) was closed in March 2018. Since then all HRNBL1 patients are being registered and treated according SIOPEN standard recommendation as defined in protocol v1.8. For these patients the use of ch14.18/CHO antibody is recommended without scIL-2 as continuous infusion as standard of care outside of controlled trials. ch14.18/CHO received marketing authorization by EMA in May 2017 (Qarziba ®).In the induction phase, all patients receive Rapid COJEC following the result of the R3 randomization which was closed on June 8th, 2017 after inclusion of 630 patients as planned. Following induction treatment peripheral blood stem cell harvest (PBSCH) is performed and complete excision of the primary tumour will be attempted. Patients with an inadequate metastatic response to allow BuMel MAT followed by PBSCR at the end of induction should receive 2 TVD (Topotecan, Vincristine, Doxorubicin) cycles. After Rapid COJEC induction, localized patients will proceed to consolidation. Patients aged 12-18 months at diagnosis, with stage 4 neuroblastoma, no MYCN amplification and without segmental chromosomal alterations (SCAs) are thought to have a good prognosis and will stop treatment after induction therapy and surgery to the primary tumour.Consolidation consists of BuMel MAT based on the results of the R1 randomization followed by peripheral blood stem cell rescue (PBSCR) and radiotherapy to the site of the primary tumour. With amendment 1.9 the End of recruitment was prolonged to Q2 2023 followed by a 5-year patient follow-up period.

Conditions

  • Neuroblastoma

Interventions

  • VincristineDrug

    given during Rapid COJEC and modified N7 therapy

  • AldesleukinDrug

    Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2

  • ch14.18/CHODrug

    ch14.18/CHO antibody is given during MRD treatment

  • CarboplatinDrug

    Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)

  • EtoposideDrug

    Etoposide is given during Induction Treatment (both R3 randomisation arms)

  • CisplatinDrug

    Cisplatin is given during Induction Treatment (both R3 randomisation arms)

  • CyclophosphamideDrug

    Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)

  • DoxorubicinDrug

    Doxorubicin is given during Induction Treatment (R3 arm modified N7)

  • G-CSFDrug

    G-CSF is given during Induction Treatment

  • BusulfanDrug

    In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.

  • MelphalanDrug

    Melphalan is given during MAT treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event Free Survival (R1: MAT therapy)Time frame: Up to three years
  2. Event Free Survival (immunotherapy)Time frame: Up to three years
  3. Complete metastatic response (R3: Induction therapy)Time frame: Up to 95 days
  4. Event free survival (R3: Induction therapy)Time frame: Up to three years

Locations

122 sites in 20 countries. Site status is shown where the registry gives one.

  • The John Hunter Children's Hospital

    Newcastle, Australia

  • Sydney Children's Hospital

    Sydney, Australia

  • Univ.-Klinik für Kinder- und Jugendheilkunde Graz

    Graz, Austria

  • Univ.Klinik f. Kinder-u. Jugendheilkunde Innsbruck

    Innsbruck, Austria

  • Landes- Kinderklinik Linz

    Linz, Austria

  • St. Johanns Spital LKH Salzburg

    Salzburg, Austria

  • St. Anna Kinderspital

    Vienna, Austra, Austria

  • Cliniques universitaires St-Luc

    Brussels, Belgium

  • Hôpital des Enfants

    Brussels, Belgium

  • University Hospital Gent

    Ghent, Belgium

  • UZ Gasthuisberg

    Leuven, Belgium

  • CHR Citadelle

    Liège, Belgium

  • Clinique de l'Espérance

    Montegnée, Belgium

  • University Hospital Motol

    Prague, Czechia

  • Aarhus Universitetshospital

    Aarhus, Denmark

  • National State Hospital

    Copenhagen, Denmark

  • University Hospital of Odense

    Odense, Denmark

  • Skejby Hospital

    Skejby, Denmark

  • Hopital d'Enfants Dijon

    Dijon, France

  • CHU de Grenoble

    Grenoble, France

  • CHR Pellegrin

    Le Pellerin, France

  • Centre Oscar Lambret de Lille

    Lille, France

  • Hopitaux de Marseille La Timone

    Marseille, France

  • CHR de Nantes

    Nantes, France

  • Hôpital Trousseau Paris

    Paris, France

  • Institut Curie

    Paris, France

  • Hôpital American Memorial Hospital

    Reims, France

  • CHU-Saint Etienne

    Saint-Etienne, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Hôpital D'Enfants de Toulouse

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • "A&P Kyriakou" Children's Hospital

    Athens, Greece

  • Aghia Sophia Children's Hospital

    Athens, Greece

  • MITERA Hospital

    Heraklion, Greece

  • PEPAGNH University Hospital

    Heraklion, Greece

  • Madarász Children Hospital Budapest

    Budapest, Hungary

  • Semmelweis University of Budapest

    Budapest, Hungary

  • University of Debrecen

    Debrecen, Hungary

  • University of Pecs

    Pécs, Hungary

  • University of Szeged

    Szeged, Hungary

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.